Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Sirion introduces topical ophthalmic pain drug
Durezol, which was approved by the FDA in June 2008, is a topical ophthalmic corticosteroid indicated for the treatment of inflammation and pain associated with ocular surgery. Susan
Durezol, which was approved by the FDA in June 2008, is a topical ophthalmic corticosteroid indicated for the treatment of inflammation and pain associated with ocular surgery. Susan
Ovation acquired the exclusive US license to ATryn from GTC Biotherapeutics, allowing the company to develop and commercialize the product in the US. The acceptance of the biologics
Biocept also appointed Edward Dennis as a director. The company announced the resignation of its former CEO, president and director, Gordon Janko. Dr Coutts has 30 years of
Patient care at the clinic is expected to commence soon, with the first patients scheduled to arrive on October 8, 2008. Clinical services at the Guangzhou facility will
Ms Aubuchon will be responsible for GenomeQuest’s worldwide financial operations, ensuring that the company maintains the financial infrastructure necessary to successfully execute the company’s strategic plan. Ms Aubuchon
Work carried out at the Breakthrough Breast Cancer Research Centre and at the Cancer Research UK Centre for Cancer Therapeutics, both of which are at The Institute of
Both companies believe that this hire will accelerate Focus Surgery’s (FSI’s) ability to expand its high intensity focused ultrasound (HIFU) technology platform. As the director of regulatory affairs,
Results show Cleviprex (clevidipine butyrate) injectable emulsion is safe and effective for managing blood pressure in patients undergoing cardiac surgery and provides more precise blood pressure control than
This was the third of several regularly scheduled reviews by the data safety monitoring board (DSMB) that will occur over the duration of the trial. The purpose of
Under the terms of the agreement, Lilly (through a wholly owned subsidiary) will acquire ImClone, followed by a merger of Lilly’s subsidiary with ImClone. Lilly is expected to